Dapagliflozin (Synonyms: 达格列净; BMS-512148)

目录号: HY-10450 纯度: 99.97%: Data Sheet SDS COA 产品使用指南技术支持

溶解度

动物溶解方案

Dapagliflozin (BMS-512148) 是一种竞争性葡萄糖协同转运蛋白2 (SGLT2) 抑制剂，可导致尿液中葡萄糖的排泄，用于糖尿病 (DM) 的研究。Dapagliflozin 诱导 HIF1 表达并减轻肾脏 IR 损伤。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Dapagliflozin Chemical Structure

CAS No. : 461432-26-8

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥825	In-stock
5 mg	￥750	In-stock
10 mg	￥1100	In-stock
50 mg	￥2750	In-stock
100 mg	￥4500	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Dapagliflozin:

Dapagliflozin-d₅ In-stock
Dapagliflozin ((2S)-1,2-propanediol, hydrate) In-stock
Dapagliflozin-¹³C₆-1 询价
Dapagliflozin (Standard) 询价

MCE 顾客使用本产品发表的 43 篇科研文献

Cell Viability Assay

: Dapagliflozin purchased from MCE. Usage Cited in: Life Sci. 2023 Apr 4;121671. [Abstract]; Dapagliflozin (DAPA; 10 μM; 24 hours) significantly decreases the expression of YAP/TAZ and increases the ratios of p-YAP/YAP and pTAZ/TAZ under high glucose conditions in HK-2 cells.

: Dapagliflozin purchased from MCE. Usage Cited in: Life Sci. 2023 Apr 4;121671. [Abstract]; Dapagliflozin (DAPA; 10, 20 μM; 24 h) significantly reverses the decrease in cell viability caused by high glucose in HK-2 cells.

: Dapagliflozin purchased from MCE. Usage Cited in: Life Sci. 2023 Apr 4;121671. [Abstract]; Dapagliflozin (DAPA; 10 μM; 24 hours) significantly reduces the high glucose-induced increase in YAP/TAZ expression in HK-2 cells.

: Dapagliflozin purchased from MCE. Usage Cited in: EBioMedicine. 2022, 86: 104342.; Dapagliflozin increases the LC3-II to LC3-I expression ratio in the liver.

: Dapagliflozin purchased from MCE. Usage Cited in: Biochem Pharmacol. 2018 Jun;152:45-59. [Abstract]; Effects of Dapagliflozin and Empagliflozin on p62 expression in LPS-untreated and LPS-treated RAW264.7 cells.

: Dapagliflozin purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2018;45(5):1747-1758. [Abstract]; The expression of IRS1 significantly decreases. The phosphorylation levels of Akt1, Akt2, and S6 are significantly reduced in livers of db/db mice.

Dapagliflozin 相关产品

•相关化合物库:

查看 SGLT 亚型特异性产品:

查看所有亚型

SGLT1 SGLT2

生物活性
纯度 & 产品资料
参考文献

生物活性

Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine^[1]. Dapagliflozin induces HIF1 expression and attenuates renal IR injury^[2].

IC₅₀ & Target

SGLT2

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
CHO	IC₅₀	0.004 μM Compound: 2	Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting	[PMID: 21398124]
CHO	IC₅₀	0.022 μM Compound: 2	Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting in presence of 100% plasma Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting in presence of 100% plasma	[PMID: 21398124]
CHO	IC₅₀	0.37 μM Compound: 2	Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting	[PMID: 21398124]
CHO	IC₅₀	0.38 μM Compound: 2	Inhibition of SGLT6 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting Inhibition of SGLT6 expressed in CHO cells assessed as inhibition of [14C]-alpha-methyl-D-glucopyranoside transport after 60 mins by scintillation counting	[PMID: 21398124]
CHO	IC₅₀	0.49 nM Compound: 1	Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting	[PMID: 24900297]
CHO	IC₅₀	0.49 nM Compound: Dapagliflozin	Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting	[PMID: 21906953]
CHO	IC₅₀	0.49 nM Compound: 1	Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting	[PMID: 21193308]
CHO	IC₅₀	0.49 nM Compound: 1	Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting	[PMID: 20434909]
CHO	IC₅₀	0.49 nM Compound: 9	Inhibition of human recombinant SGLT2 expressed in CHO cells by liquid scintillation counting Inhibition of human recombinant SGLT2 expressed in CHO cells by liquid scintillation counting	[PMID: 20181486]
CHO	IC₅₀	0.49 nM Compound: 1	Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counter Inhibition of human SGLT2 expressed in CHO cells assessed as [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counter	[PMID: 21514014]
CHO	IC₅₀	1.3 nM Compound: 4	Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins	[PMID: 22889351]
CHO	IC₅₀	1.35 nM Compound: Dapagliflozin	Inhibition of human SGLT2 expressed in CHO cells assessed as reduction of [14C]-labeled AMG after 2 hrs by liquid scintillation counting Inhibition of human SGLT2 expressed in CHO cells assessed as reduction of [14C]-labeled AMG after 2 hrs by liquid scintillation counting	[PMID: 21868239]
CHO	IC₅₀	1.35 nM Compound: 1	Inhibition of human SGLT2 expressed in CHO cells using methyl-alpha-D-glucopyranoside by liquid scintillation counting Inhibition of human SGLT2 expressed in CHO cells using methyl-alpha-D-glucopyranoside by liquid scintillation counting	[PMID: 21592794]
CHO	IC₅₀	1.4 nM Compound: 2	Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent methyl-alpha-D-[U-14C]glucopyranoside uptake after 2 hrs Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent methyl-alpha-D-[U-14C]glucopyranoside uptake after 2 hrs	[PMID: 20149653]
CHO	IC₅₀	1200 nM Compound: 2	Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent methyl-alpha-D-[U-14C]glucopyranoside uptake after 2 hrs Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent methyl-alpha-D-[U-14C]glucopyranoside uptake after 2 hrs	[PMID: 20149653]
CHO	EC₅₀	3 nM Compound: 5	Inhibition of human SGLT2 expressed in CHO cells assessed as sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting Inhibition of human SGLT2 expressed in CHO cells assessed as sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting	[PMID: 21128592]
CHO	IC₅₀	3 nM Compound: Dapagliflozin	Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-Glucose uptake using [14C]-methyl glucopyranoside after 60 mins by microbeta plate counting Inhibition of human SGLT2 expressed in CHO cells assessed as inhibition of [14C]-Glucose uptake using [14C]-methyl glucopyranoside after 60 mins by microbeta plate counting	[PMID: 21565497]
CHO	EC₅₀	428.5 nM Compound: 5	Inhibition of human SGLT1 expressed in CHO cells assessed as sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting Inhibition of human SGLT1 expressed in CHO cells assessed as sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting	[PMID: 21128592]
CHO	IC₅₀	5 nM Compound: 12	Competitive inhibition of full-length human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by scintillation counting Competitive inhibition of full-length human SGLT2 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]-alpha-methyl-D-glucopyranoside uptake after 2 hrs by scintillation counting	[PMID: 25650254]
CHO	IC₅₀	800 nM Compound: 4	Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins Inhibition of human SGLT1 expressed in CHO cells assessed as inhibition of sodium-dependent [14C]methyl-alpha-D-glucopyranoside uptake after 45 mins	[PMID: 22889351]
CHO-K1	IC₅₀	1 nM Compound: 1	Inhibition of human SGLT2 expressed in CHOK1 cells assessed as inhibition of [14C]-AMG uptake after 3 hrs by microbeta scintillation counting analysis Inhibition of human SGLT2 expressed in CHOK1 cells assessed as inhibition of [14C]-AMG uptake after 3 hrs by microbeta scintillation counting analysis	[PMID: 24842618]
CHO-K1	IC₅₀	1.3 nM Compound: 3	Inhibition of human SGLT2 expressed in CHO-K1 cells by [14C]AMG uptake assay Inhibition of human SGLT2 expressed in CHO-K1 cells by [14C]AMG uptake assay	[PMID: 22652255]
CHO-K1	EC₅₀	2.4 nM Compound: 12	Inhibition of human SGLT2 expressed in CHO-K1 cells incubated for 120 mins at 37 degC by [14C]-AMG uptake assay Inhibition of human SGLT2 expressed in CHO-K1 cells incubated for 120 mins at 37 degC by [14C]-AMG uptake assay	[PMID: 22818040]
CHO-K1	EC₅₀	593 nM Compound: 12	Inhibition of human SGLT1 expressed in CHO-K1 cells incubated for 120 mins at 37 degC by [14C]-AMG uptake assay Inhibition of human SGLT1 expressed in CHO-K1 cells incubated for 120 mins at 37 degC by [14C]-AMG uptake assay	[PMID: 22818040]
CHO-K1	IC₅₀	800 nM Compound: 3	Inhibition of human SGLT1 expressed in CHO-K1 cells by [14C]AMG uptake assay Inhibition of human SGLT1 expressed in CHO-K1 cells by [14C]AMG uptake assay	[PMID: 22652255]
CHO-K1	IC₅₀	891 nM Compound: 1	Inhibition of human SGLT1 expressed in CHOK1 cells assessed as inhibition of [14C]-AMG uptake after 3 hrs by microbeta scintillation counting analysis Inhibition of human SGLT1 expressed in CHOK1 cells assessed as inhibition of [14C]-AMG uptake after 3 hrs by microbeta scintillation counting analysis	[PMID: 24842618]
COS-7	IC₅₀	0.89 μM Compound: 1	Inhibition of human SGLT1 expressed in african green monkey COS7 cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting Inhibition of human SGLT1 expressed in african green monkey COS7 cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 2 hrs by liquid scintillation counting	[PMID: 20576578]
COS-7	IC₅₀	0.89 μM Compound: 2	Inhibition of human SGLT1 transfected in COS-7 cells assessed as AMG uptake after 2 hrs by scintillation counting Inhibition of human SGLT1 transfected in COS-7 cells assessed as AMG uptake after 2 hrs by scintillation counting	[PMID: 19896374]
COS-7	IC₅₀	3.2 nM Compound: 1	Inhibition of human SGLT2 expressed in african green monkey COS7 cells assessed as inhibition of [14C]-methyl-alpha-D-glucopyranoside uptake after 2 hrs by scintillation counting in presence of 25 % human plasma Inhibition of human SGLT2 expressed in african green monkey COS7 cells assessed as inhibition of [14C]-methyl-alpha-D-glucopyranoside uptake after 2 hrs by scintillation counting in presence of 25 % human plasma	[PMID: 21737266]
COS-7	IC₅₀	885 nM Compound: 1	Inhibition of human SGLT1 expressed in african green monkey COS7 cells assessed as methyl-alpha-D-[U-14C]glucopyranoside uptake by scintillation counting Inhibition of human SGLT1 expressed in african green monkey COS7 cells assessed as methyl-alpha-D-[U-14C]glucopyranoside uptake by scintillation counting	[PMID: 19700318]
HEK293	IC₅₀	0.0008 μM Compound: 4a	Inhibition of human SGLT2 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay Inhibition of human SGLT2 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay	[PMID: 28098449]
HEK293	IC₅₀	1.8 μM Compound: 4a	Inhibition of human SGLT1 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay Inhibition of human SGLT1 expressed in HEK293 cells assessed as reduction in 2-deoxyglucose uptake pretreated for 10 mins followed by 2-deoxyglucose addition in presence of sodium buffer measured after 1 hr by resazurin dye based fluorescence assay	[PMID: 28098449]
HEK293	IC₅₀	3100 nM Compound: 1	Inhibition of human SGLT1 expressed in human 293 cells assessed as inhibition of [14C]-methyl-alpha-D-glucopyranoside uptake after 1.5 hrs by scintillation counting in presence of 25 % human plasma Inhibition of human SGLT1 expressed in human 293 cells assessed as inhibition of [14C]-methyl-alpha-D-glucopyranoside uptake after 1.5 hrs by scintillation counting in presence of 25 % human plasma	[PMID: 21737266]
HEK293	IC₅₀	6.7 nM Compound: 1	Inhibition of human SGLT2 expressed in HEK293 cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 1.5 hrs by liquid scintillation counting Inhibition of human SGLT2 expressed in HEK293 cells assessed as inhibition of [14C]alpha-methyl-D-glucopyranoside uptake after 1.5 hrs by liquid scintillation counting	[PMID: 20576578]
NIH3T3	IC₅₀	12.3 μM Compound: 2	Inhibition of human full length SGLT1 expressed in NIH3T3 cells measured after 1 hr in presence of [14C]-methyl-alpha -D-glucopyranoside by scintillation counter method Inhibition of human full length SGLT1 expressed in NIH3T3 cells measured after 1 hr in presence of [14C]-methyl-alpha -D-glucopyranoside by scintillation counter method	[PMID: 31325786]
NIH3T3	IC₅₀	8.3 nM Compound: 2	Inhibition of human full length SGLT2 expressed in NIH3T3 cells measured after 1 hr in presence of [14C]-methyl-alpha -D-glucopyranoside by scintillation counter method Inhibition of human full length SGLT2 expressed in NIH3T3 cells measured after 1 hr in presence of [14C]-methyl-alpha -D-glucopyranoside by scintillation counter method	[PMID: 31325786]

体外研究
(In Vitro)

Dapagliflozin (0-10 μM；24 小时) 以剂量依赖性方式显着增加缺氧 HK2 细胞中的细胞存活率^[2]。
Dapagliflozin (0-10 μM；2 小时) 增加缺氧 HK2 细胞中 HIF1 表达，增加 AMPK 和 EKR 磷酸化，但对常氧 HK2 细胞中 AMPK 和 ERK 磷酸化没有影响^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Hypoxic HK2 cells
Concentration:	0 μM, 1 μM, 2 μM, 5 μM, 10 μM
Incubation Time:	24 hours
Result:	Improved the cell viability in a dose-dependent manner compared with control cells.

Western Blot Analysis^[1]

Cell Line:	Hypoxic HK2 cells, Normoxic HK2 cells
Concentration:	0 μM, 1 μM, 2 μM, 5 μM, 10 μM
Incubation Time:	24 hours
Result:	Induced HIF1 expression in hypoxic and normoxic HK2 cells.

体内研究
(In Vivo)

Dapagliflozin（口服；10 mg/kg）可导致 SGLT2i 小鼠尿糖显著增加，通过降低交感神经活动抑制 BAT 产热，并增强肝脏糖异生和糖原分解^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04545411	University of California, San Diego\|REMD Biotherapeutics, Inc.\|Juvenile Diabetes Research Foundation\|The Leona M. and Harry B. Helmsley Charitable Trust	Type 1 Diabetes	February 22, 2021	Phase 1\|Phase 2
NCT03316131	AstraZeneca\|Contract Research Organization: USA\|PAREXEL Early Phase Clinical Unit Baltimore\|PAREXEL Early Phase Clinical Unit-Los Angeles\|Clinical Laboratory: USA\|Harbor Hospital Laboratory\|GenX Laboratories Inc.\|Analytical Laboratory (Pharmacokinetic Sample Analysis): USA\|Covance Bioanalytical Services, LLC	Asymptomatic Hyperuricemia	October 25, 2017	Phase 2
NCT04780438	G.Gennimatas General Hospital\|2nd Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens	Atrial Fibrillation Recurrent\|Pulmonary Venous Isolation\|Catheter Ablation\|Sodium-glucose Co-transporter 2 Inhibitors	September 1, 2021	Early Phase 1
NCT04743453	University of Sao Paulo General Hospital\|Federal University of São Paulo	Kidney Transplantation\|Diabetes Mellitus, Type 2\|Diabetes Complications	August 17, 2021	Phase 4
NCT03089333	University of Campinas, Brazil\|Fundação de Amparo à Pesquisa do Estado de São Paulo	Hypertension\|Diabetes Mellitus, Type 2\|Blood Pressure\|Obesity\|Cardiac Hypertrophy\|Microalbuminuria\|Vascular Stiffness	July 2016	Phase 4
NCT05735197	Mansoura University	Chronic Kidney Diseases\|Bone Diseases, Metabolic	November 10, 2022	Phase 4
NCT02518945	University at Buffalo	Type 1 Diabetes Mellitus	August 2015	Phase 3
NCT02433678	University at Buffalo\|Kaleida Health	Type 2 Diabetes	November 2015	Phase 4
NCT05965440	Hospices Civils de Lyon	Chronic Kidney Diseases	September 1, 2023	Not Applicable
NCT01877889	Janssen-Cilag International NV	Healthy	July 2013	Phase 1
NCT03919656	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	Type 2 Diabetes Mellitus	May 2019	Phase 4
NCT05347459	Alexandria University	Type 2 Diabetes	March 2, 2022
NCT02460978	AstraZeneca\|Bristol-Myers Squibb	Type 1 Diabetes Mellitus	July 8, 2015	Phase 3
NCT05719714	Northwestern University\|National Institutes of Health (NIH)\|National Heart, Lung, and Blood Institute (NHLBI)	Chronic Kidney Diseases\|Heart Failure With Preserved Ejection Fraction\|Kidney Diseases\|Heart Failure	September 1, 2023	Phase 1\|Phase 2
NCT02383238	University of Erlangen-Nürnberg Medical School	Diabetes Mellitus Type 2	March 2014	Phase 3
NCT05986136	Mostafa Bahaa\|Tanta University	Inflammatory Bowel Diseases	August 20, 2023	Phase 2\|Phase 3
NCT00976495	AstraZeneca\|Astra Zeneca, Bristol-Myers Squibb	Type 2 Diabetes Mellitus	October 2009	Phase 2
NCT00736879	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	September 22, 2008	Phase 3
NCT04794517	Mario Negri Institute for Pharmacological Research\|AstraZeneca	Chronic Kidney Diseases	November 8, 2021	Phase 2
NCT02610088	Seoul National University Bundang Hospital	Diabetes	November 2015	Phase 4
NCT04492722	AstraZeneca\|Parexel\|George Clinical Pty Ltd	Chronic Kidney Disease	October 1, 2020	Phase 2
NCT03887416	LM Diagnósticos S.L.\|AstraZeneca	Type2 Diabetes	April 12, 2019	Phase 4
NCT05343078	University of Campinas, Brazil	End-stage Renal Disease	April 25, 2022	Phase 4
NCT05330013	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Myocardial Dysfunction\|Heart Failure\|Inflammation	June 23, 2022	Phase 2
NCT01217892	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	November 2010	Phase 3
NCT01095653	AstraZeneca\|AstraZeneca, Bristol-Myers Squibb	Type 2 Diabetes	June 2010	Phase 3
NCT03723252	Nanfang Hospital, Southern Medical University	Nonalcoholic Steatohepatitis	March 20, 2019	Phase 3
NCT02096705	AstraZeneca\|Bristol-Myers Squibb	Diabetes	March 31, 2014	Phase 3
NCT04304430	University of Padova	Type 2 Diabetes	October 18, 2018
NCT04869124	Frank Ruschitzka\|AstraZeneca\|University of Zurich	Heart Failure?Congestive	February 15, 2021	Phase 4
NCT05392959	Centre Hospitalier Universitaire Saint Pierre\|AstraZeneca	Diabetes Mellitus, Type 2	June 6, 2022	Phase 4
NCT04170998	Dong-A ST Co., Ltd.	Type2 Diabetes	January 2, 2020	Phase 3
NCT05025735	Saint Luke´s Health System\|Novartis Pharmaceuticals	Metastatic Breast Cancer\|HER2-negative Breast Cancer	August 25, 2021	Phase 2
NCT01619059	AstraZeneca	Type 2 Diabetes	June 2012	Phase 3
NCT02798757	University of Ioannina	Diabetes	June 2016	Phase 4
NCT03202563	LG Chem	Type 2 Diabetes Mellitus	August 9, 2017	Phase 4
NCT04333823	The Hospital for Sick Children\|Canadian Institutes of Health Research (CIHR)\|Juvenile Diabetes Research Foundation	Diabetes Mellitus, Type 1	December 11, 2020	Phase 3
NCT04887935	Washington University School of Medicine	Prostate Cancer\|Cancer of Prostate	December 31, 2023	Phase 1
NCT02984644	The University of Texas Health Science Center at San Antonio	Type II; Diabetes	September 6, 2017	Phase 3
NCT02235298	University of Miami\|AstraZeneca	Type 2 Diabetes	September 2015	Phase 4
NCT01294423	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes\|High Blood Sugar	February 2011	Phase 3
NCT02338921	Seoul National University Bundang Hospital	Type 2 Diabetes	January 2015	Phase 4
NCT02372955	Gulf Regional Research & Educational Services, LLC	Diabetes Mellitus Type 2	February 2015	Phase 4
NCT02719132	AstraZeneca	Diabetes Mellitus Type 2	July 2016	Phase 4
NCT01646320	AstraZeneca	Type 2 Diabetes	September 2012	Phase 3
NCT05321706	Oslo University Hospital\|Erasmus Medical Center\|Skane University Hospital\|Aarhus University Hospital\|Karolinska University Hospital\|Sahlgrenska University Hospital, Sweden	Heart Transplant Failure\|Kidney Failure	June 8, 2022	Phase 3
NCT00930865	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	July 2009	Phase 1
NCT03782259	University of Washington\|AstraZeneca	Type 2 Diabetes Mellitus\|Myocardial Fibrosis\|Myocardial Inflammation	February 26, 2019	Phase 4
NCT03180489	Christopher Bell\|AstraZeneca\|Colorado State University	Weight Loss	May 3, 2017	Phase 2
NCT01137474	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	July 2010	Phase 3
NCT00528372	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	September 2007	Phase 3
NCT05741658	Johns Hopkins University\|University of California, Los Angeles\|Brett Boyer Foundation\|AstraZeneca	Heart Failure	August 2023	Phase 4
NCT05591235	Nanjing First Hospital, Nanjing Medical University	Type2diabetes\|Insulin Resistance	November 2022	Phase 3
NCT02981966	The University of Texas Health Science Center at San Antonio\|AstraZeneca	Diabetes Mellitus, Type 2	May 23, 2019	Phase 4
NCT04783870	Instituto Mexicano del Seguro Social	Myocardial Infarction	March 3, 2021	Phase 4
NCT04965935	University Health Network, Toronto	Kidney Transplant Recipients\|Post-transplant Diabetes Mellitus\|Type 2 Diabetes	July 15, 2021	Phase 3
NCT04620590	George Clinical Pty Ltd\|University Medical Center Groningen\|Ground Zero Pharmaceuticals	Diabetes Mellitus, Type 2\|Impaired Renal Function	April 20, 2021	Phase 4
NCT05443932	Medical University of Vienna	Urolithiasis\|Hyperoxaluria	October 3, 2022	Phase 4
NCT04200586	The University of Hong Kong	Type2 Diabetes\|Heart Failure With Reduced Ejection Fraction	April 9, 2020	Phase 4
NCT04792190	University of Rochester\|AstraZeneca	Atrial Fibrillation	July 27, 2021	Phase 4
NCT04591639	University of Edinburgh\|AstraZeneca\|NHS Lothian	Heart Failure\|Diabetic Cardiomyopathies	August 19, 2020	Not Applicable
NCT05305911	Minneapolis Heart Institute Foundation	Heart Attack\|Enlarged Heart	August 3, 2022	Phase 2
NCT04401904	The University of Texas Health Science Center at San Antonio\|National Institute on Aging (NIA)	Aging	June 25, 2020	Phase 1\|Phase 2
NCT05849766	October 6 University\|Beni-Suef University\|National Heart Institute, Egypt	Dilated Cardiomyopathy	April 27, 2023	Phase 3
NCT02796170	Tulane University School of Medicine\|AstraZeneca\|Tulane University	Type 2 Diabetes\|Hypertension	March 2016	Phase 4
NCT03801642	Jeff Burns, MD\|University of Kansas Medical Center	Alzheimer Disease	January 29, 2019	Phase 1\|Phase 2
NCT05250752	Holbaek Sygehus	End Stage Renal Disease\|Peritoneal Dialysis Complication	November 18, 2021	Phase 2
NCT05686616	Samsung Medical Center	Tricuspid Regurgitation	April 13, 2022	Not Applicable
NCT05266404	AstraZeneca\|Parexel	Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)	March 21, 2022	Phase 1
NCT04534270	Children´s Hospital of Fudan University	Proteinuria	July 6, 2020	Phase 4
NCT03036124	AstraZeneca	Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)	February 8, 2017	Phase 3
NCT03871621	Mackay Memorial Hospital	Type 2 Diabetes Mellitus	April 1, 2019	Phase 4
NCT02681094	AstraZeneca	Type 2 Diabetes Mellitus\|Inadequate Glycaemic Control	February 26, 2016	Phase 3
NCT02420392	Seoul National University Hospital\|AstraZeneca	Diabetes Mellitus, Type 2	February 2015	Not Applicable
NCT03721874	Maastricht University\|AstraZeneca	Prediabetic State\|Substrate Oxidation	April 30, 2019	Phase 4
NCT02459353	The Catholic University of Korea\|AstraZeneca\|Severance Hospital\|Eulji General Hospital\|Kyung Hee University Hospital at Gangdong	Type 2 Diabetes Mellitus	August 2015	Phase 4
NCT05570305	University Medical Center Groningen\|AstraZeneca	Chronic Kidney Diseases	October 6, 2022	Phase 2
NCT04393246	Cambridge University Hospitals NHS Foundation Trust	COVID-19	July 3, 2020	Phase 2\|Phase 3
NCT00546741	AstraZeneca\|Bristol-Myers Squibb	Healthy Male and Female Subjects	November 2007	Phase 1
NCT04475042	Mariëlle Scheffer\|AstraZeneca\|Onze Lieve Vrouwe Gasthuis	Heart Failure, Diastolic	July 1, 2020	Phase 2
NCT01439854	The University of Texas Health Science Center at San Antonio\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Insulin Sensitivity\|Multiple Mitochondrial Dysfunctions Syndrome	March 2011	Not Applicable
NCT02577159	Osaka University	Diabetes Mellitus, Type 2	July 1, 2015	Phase 4
NCT04215523	Brigham and Women´s Hospital	Diabetes	July 8, 2019
NCT05390307	Dasman Diabetes Institute	Type 1 Diabetes	February 1, 2023	Not Applicable
NCT05676684	Universidade do Porto\|Centro Hospitalar Universitário de São João, E.P.E.\|Centro Hospitalar de Vila Nova de Gaia+Espinho, E.P.E.	Heart Failure With Preserved Ejection Fraction	September 15, 2022	Phase 2\|Phase 3
NCT02879409	Weill Cornell Medical College in Qatar\|Hamad Medical Corporation\|Sidra Medical and Research Center\|University of Hull	Diabetes Mellitus Type 2	November 2016	Not Applicable
NCT05886088	EMS	Type 2 Diabetes Mellitus	February 2024	Phase 3
NCT00263276	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	December 2005	Phase 2
NCT05713851	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran\|Olynka Vega Vega\|Noemi del Toro Cisneros\|Miguel �ngel Martínez Rojas	AKI - Acute Kidney Injury\|Biomarkers\|Transition to CKD\|CKD	January 1, 2023	Phase 2\|Phase 3
NCT01031680	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus\|Cardiovascular Disease\|Hypertension\|Inadequate Glycaemic Control	February 2010	Phase 3
NCT00683878	AstraZeneca\|Astra Zeneca, Bristol-Myers Squibb	Type 2 Diabetes	July 2008	Phase 3
NCT03499704	Celltrion Pharm, Inc.	Diabetes Mellitus, Type 2	February 11, 2020	Phase 4
NCT03565458	LG Chem	Type 2 Diabetes Mellitus	April 5, 2018	Phase 1
NCT00660907	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	March 2008	Phase 3
NCT05406505	Mansoura University	Acute Heart Failure	April 25, 2022	Phase 2\|Phase 3
NCT00842556	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	March 2009	Phase 1
NCT04880993	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Healthy Subjects	December 14, 2020	Phase 1
NCT05174052	University of Oklahoma	Diabete Mellitus\|Atrial Fibrillation	June 1, 2022	Phase 3
NCT03387683	AstraZeneca	Diabetes Mellitus Type 2	February 28, 2018	Phase 4
NCT04564742	AstraZeneca\|Uppsala University	Acute Myocardial Infarction\|Heart Failure	December 22, 2020	Phase 3
NCT05418946	University of Milan	Type 2 Diabetes	June 2022
NCT04350593	Saint Luke´s Health System\|Saint Luke´s Hospital of Kansas City\|AstraZeneca\|George Clinical Pty Ltd	COVID-19	April 22, 2020	Phase 3
NCT00663260	AstraZeneca\|Bristol-Myers Squibb	Diabetes Mellitus, Type 2	June 2008	Phase 2\|Phase 3
NCT02616666	University of Liverpool\|AstraZeneca\|Clinical Practice Research Datalink	Type 2 Diabetes Mellitus	August 25, 2016	Phase 4
NCT02419612	AstraZeneca	Diabetes	August 14, 2015	Phase 3
NCT05359263	Tor Biering-Sørensen\|Herlev and Gentofte Hospital	Chronic Kidney Diseases	June 8, 2022	Phase 2
NCT05045274	Assiut University	STEMI - ST Elevation Myocardial Infarction\|Left Ventricular Systolic Dysfunction	December 2021	Not Applicable
NCT05710367	Albina Nowak, MD\|University of Zurich	Fabry Disease	August 2023	Phase 2
NCT02279407	AstraZeneca\|Uppsala Clinical Research, Uppsala, Sweden	T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)	January 2015	Phase 2
NCT03269058	Centre Hospitalier Universitaire Dijon	Type-2 Diabetes\|Oral Antidiabetics	December 20, 2017	Phase 4
NCT04956263	Youngene Therapeutics Inc., Ltd.\|ProSciento, Inc.	Diabetes\|Diabetes Mellitus, Type 1\|Type1diabetes\|Diabetes Mellitus	June 17, 2021	Phase 2
NCT03398577	Sheba Medical Center	Coronary Disease With Diabetes Mellitus	February 1, 2018	Phase 4
NCT03169959	AstraZeneca\|Parexel	Type 2 Diabetes Mellitus	May 29, 2017	Phase 1
NCT02695810	Steno Diabetes Center Copenhagen\|The Novo Nordic Foundation\|Rigshospitalet, Denmark\|AstraZeneca\|Bayer	Prediabetic State\|Obesity	February 24, 2016	Phase 2
NCT02751398	Yonsei University	Type 2 Diabetes Mellitus	August 18, 2016	Phase 4
NCT01392677	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus\|High HbA1c Level\|Inadequate Glycaemic Control	October 2011	Phase 3
NCT05776043	Medical University of Warsaw\|Medical University of Vienna\|Medical University of Graz\|University Clinical Center of the Medical University of Warsaw\|Jerzy Popie?uszko Biela?ski Hospital in Warsaw\|Regional Polyclinical Hospital in Kielce\|University Clinical Hospital Military Medical Academy, Central Veterans Hospital in ?ód?\|Medical University of Gdansk\|Autonomous Public Specialist Western John Paul II Hospital in Grodzisk Mazowiecki\|Nicolaus Copernicus University in Toru?, Collegium Medicum in Bydgoszcz\|Poznan University of Medical Sciences\|John Paul II Specialist Hospital in Kraków\|Ludwik Rydygier Regional Polyclinical Hospital in Toru?\|University Teaching Hospital in Bia?ystok\|Medical University of Silesia in Katowice	Acute Decompensated Heart Failure	March 15, 2022	Phase 3
NCT05989347	Yale University\|AstraZeneca	Breast Cancer\|Hyperinsulinism\|HER2-negative Breast Cancer	September 2023	Phase 1
NCT03492580	Janssen Research & Development, LLC	Diabetes Mellitus, Type 2\|Cardiovascular Diseases	February 22, 2018
NCT01055691	AstraZeneca\|Bristol-Myers Squibb	Healthy Volunteers	January 2010	Phase 1
NCT02426541	AstraZeneca\|Antaros Medical\|Bioventure Hub\|43183 Mölndal\|Sweden	Type 2 Diabetes Mellitus	March 23, 2015	Phase 4
NCT05884866	Klinikum Nürnberg	Chronic Renal Failure\|Mechanistic Effects of SGLT2 Inhibition and+ or MR Antagonism on Body Fluid and Electrolyte Homeostatis	May 8, 2023	Phase 2
NCT03190694	Hiddo Lambers Heerspink\|AstraZeneca\|University Medical Center Groningen	Chronic Kidney Diseases\|Proteinuria	November 12, 2017	Phase 2
NCT04304560	Damanhour University\|Menoufia University	Heart Failure With Reduced Ejection Fraction (HFrEF)\|Diabete Type 2\|Cardiomyopathies	March 2020	Phase 2
NCT03168295	The University of Texas Health Science Center at San Antonio\|National Institutes of Health (NIH)\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Diabetes Mellitus, Type 2	October 2016	Phase 4
NCT02327039	University of Padova\|Azienda Ospedaliera di Padova	Type 2 Diabetes	March 2015	Phase 4
NCT05217654	Medical University of Vienna	Reperfusion Injury\|Vascular Complications	February 18, 2022	Phase 1
NCT02471404	AstraZeneca	Type 2 Diabetes Mellitus\|Inadequate Glycaemic Control	September 21, 2015	Phase 4
NCT04240171	Damanhour University\|Tanta University	Diabetes Mellitus, Type 2	December 1, 2020
NCT03899402	State University of New York at Buffalo\|University of Glasgow\|Juvenile Diabetes Research Foundation	Type 1 Diabetes Mellitus	May 1, 2019	Phase 2\|Phase 3
NCT04930549	University Hospital, Rouen\|AstraZeneca	Renal Insufficiency, Chronic	December 2021	Phase 2
NCT01072578	AstraZeneca\|Bristol-Myers Squibb	Healthy Volunteers	February 2010	Phase 1
NCT00688493	AstraZeneca\|Bristol-Myers Squibb	Healthy	July 2007	Phase 1
NCT01730534	AstraZeneca\|Bristol-Myers Squibb\|The TIMI Study Group\|Hadassah Medical Organization	Diabetes Mellitus, Non-Insulin-Dependent\|High Risk for Cardiovascular Event	April 25, 2013	Phase 3
NCT05704088	Mansoura University	SGLT2 INHIBITORS\|Lupus Nephritis\|BMD	October 8, 2022	Phase 4
NCT02919059	IInstituto Gallego de Medicina Vascular	Diabetes Mellitus, Type 2	December 13, 2016	Phase 4
NCT05590143	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|ZonMw: The Netherlands Organisation for Health Research and Development	Acute Kidney Injury\|Cardiac Surgery\|Sodium-Glucose Transporter 2 Inhibitor	June 9, 2023	Phase 4
NCT01095666	AstraZeneca\|AstraZeneca, Bristol-Myers Squibb	Type 2 Diabetes	June 2010	Phase 3
NCT05141552	RenJi Hospital	Hemodialysis Complication	January 3, 2022	Not Applicable
NCT03344341	AstraZeneca	Type 2 Diabetes Mellitus	December 15, 2017	Phase 4
NCT00673231	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	April 2008	Phase 3
NCT02284893	AstraZeneca	Type 2 Diabetes	September 9, 2014	Phase 3
NCT00554450	AstraZeneca\|Bristol-Myers Squibb	Diabetes Mellitus, Type 2	March 2006	Phase 1
NCT03619213	AstraZeneca	Heart Failure With Preserved Ejection Fraction	August 27, 2018	Phase 3
NCT03608358	AstraZeneca	Type 2 Diabetes Mellitus	February 27, 2019	Phase 3
NCT03419624	Universitätsklinikum Hamburg-Eppendorf\|AstraZeneca	Obesity\|Diabetes Mellitus, Type 2	February 19, 2018	Phase 3
NCT05914857	Yangjin\|Peking University Third Hospital	Prediabetic State\|Impaired Fasting Glucose\|Impaired Glucose Tolerance	December 20, 2023	Phase 2
NCT05262257	The First Affiliated Hospital with Nanjing Medical University	Type2 Diabetes	April 1, 2022	Early Phase 1
NCT05254626	Cairo University	Non-alcoholic Steatohepatitis	August 1, 2022	Phase 4
NCT00562250	AstraZeneca\|Bristol-Myers Squibb	Diabetes Mellitus, Type 2	May 2008	Phase 1
NCT01055652	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	January 2010	Phase 1
NCT03748810	Chungbuk National University Hospital	Type2 Diabetes	January 1, 2016
NCT05418465	The First Affiliated Hospital of Dalian Medical University	Diabetic Nephropathies	January 26, 2022	Not Applicable
NCT05606718	Sun Yat-sen University	Functional Mitral Regurgitation	April 1, 2022	Phase 4
NCT01662999	AstraZeneca	Type 2 Diabetes Mellitus	August 2012	Phase 1
NCT02725593	AstraZeneca\|Parexel\|Q2 Solutions\|PRA Health Sciences\|Covance Laboratories, Inc	Type 2 Diabetes	June 22, 2016	Phase 3
NCT04570865	Scripps Health	Heart Failure, Systolic	December 1, 2020	Phase 4
NCT00643851	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	June 2008	Phase 3
NCT02613897	The University of Texas Health Science Center at San Antonio\|AstraZeneca	Diabetes Mellitus, Type 2	January 2016	Not Applicable
NCT05058859	University of California, San Francisco	Cystinuria	August 1, 2023	Phase 2
NCT00726505	AstraZeneca\|Bristol-Myers Squibb	Diabetes, NOS	June 2009	Phase 1
NCT05748925	Mansoura University	SLE\|Lupus Nephritis\|SGLT2 Inhibitors	October 1, 2022	Phase 4
NCT05782972	Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation	Metabolic Associated Fatty Liver Disease	March 11, 2023	Phase 4
NCT05788276	Oslo University Hospital\|St. Olavs Hospital\|University Hospital of North Norway\|Haukeland University Hospital	Kidney Transplant; Complications\|Kidney Transplant Failure\|Renal Failure	May 2, 2023	Phase 4
NCT05226897	Yooyoung Pharmaceutical Co., Ltd.	Type 2 Diabetes	July 12, 2021	Phase 3
NCT01195662	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	October 2010	Phase 3
NCT03877237	AstraZeneca	Heart Failure With Reduced Ejection Fraction (HFrEF)	April 9, 2019	Phase 3
NCT04120623	Nanjing First Hospital, Nanjing Medical University	Type 2 Diabetes Mellitus	October 1, 2019	Phase 4
NCT02682563	M.H.H. Kramer\|AstraZeneca\|Amsterdam UMC, location VUmc	Diabetes Mellitus, Type 2\|Diabetic Nephropathies	February 2016	Phase 4
NCT00538174	AstraZeneca	Diabetes Mellitus, Type 2	November 2007	Phase 1
NCT05335629	Ain Shams University	Myocardial Infarction\|Diabetes Mellitus, Type 2\|Myocardial Remodeling, Ventricular	September 1, 2022	Not Applicable
NCT02157298	AstraZeneca	Type 2 Diabetes Mellitus	June 2014	Phase 4
NCT05435235	Albert Einstein Healthcare Network	Acute Kidney Injury\|Percutaneous Coronary Intervention	August 2023	Phase 4
NCT02719756	Research Clinical Centre of the Russian Railways, JSC	Diabetes Mellitus\|Hypoglycemic Episodes	April 2016	Phase 4
NCT03982238	Majianhua\|Nanjing First Hospital, Nanjing Medical University	Type 2 Diabetes	June 15, 2019	Phase 4
NCT05457933	Medanta, The Medicity, India	Type2diabetes\|Coronary Artery Disease	July 29, 2022	Phase 4
NCT02558270	Medical University of Vienna	Type 2 Diabetes\|Metabolically Healthy Controls	June 2016	Phase 2
NCT02313220	Uppsala University\|Uppsala University Hospital\|AstraZeneca	Obesity	December 2014	Phase 2
NCT04860011	NHS Greater Glasgow and Clyde\|University of Glasgow	Heart Failure	April 27, 2021	Phase 3
NCT03178591	Chiang Mai University	Diabetes Mellitus, Type 2\|Ischemic Heart Disease	October 2014	Phase 4
NCT03036150	AstraZeneca	Chronic Kidney Disease	February 2, 2017	Phase 3
NCT01498185	AstraZeneca\|Astra Zeneca, Bristol-Myers Squibb	Type 1 Diabetes Mellitus	February 2012	Phase 2
NCT05795400	National Medical Research Center for Cardiology, Ministry of Health of Russian Federation	Heart Failure With Reduced Ejection Fraction\|Heart Failure With Preserved Ejection Fraction\|Heart Failure With Mid Range Ejection Fraction\|Amyloid Cardiomyopathy	June 1, 2022	Not Applicable
NCT04340908	Hongchang Guo\|Beijing Anzhen Hospital	Diabetes Mellitus, Type 2\|Cardiac Surgery	January 1, 2021	Phase 4
NCT00528879	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	September 2007	Phase 3
NCT04764097	Tan Tock Seng Hospital	Cardiovascular Diseases\|End Stage Renal Disease	June 2021	Phase 2\|Phase 3
NCT04004793	Shanghai Zhongshan Hospital	Type 2 Diabetes	August 15, 2020	Phase 4
NCT05792540	Tanta University\|Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University\|Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta University\|Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University	Depressive Disorder	June 6, 2023	Phase 2
NCT05250011	AstraZeneca\|Fullcro s.r.l.	Heart Failure, Reduced Ejection Fraction	April 19, 2022
NCT03658031	Hamad Medical Corporation	PreDiabetes\|Myocardial Infarction\|T2DM (Type 2 Diabetes Mellitus)\|CVD	March 1, 2019	Phase 3
NCT05159882	Newsoara Biopharma Co., Ltd.	T2DM	April 15, 2021	Phase 3
NCT04385589	Assiut University	Heart Failure	May 1, 2020	Phase 4
NCT03074630	Amsterdam UMC, location VUmc\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Diabetes Mellitus, Type 2\|Hypercholesterolemia	May 2016	Phase 4
NCT03423355	University Hospital Tuebingen	Type 2 Diabetes Mellitus (T2DM)	September 2021	Phase 4
NCT04856007	AstraZeneca	Healthy Volunteer	April 12, 2021	Phase 1
NCT02965443	University Hospital Tuebingen	Type 2 Diabetes	February 2, 2018	Phase 4
NCT06000462	Oman Ministry of Health	Obesity\|Dapagliflozin Adverse Reaction\|Weight Loss\|Effect of Drug	December 2023	Phase 2\|Phase 3
NCT05225077	Dong-A University	Renal Insufficiency, Chronic\|Cardiac Catheterization\|Percutaneous Coronary Intervention	January 1, 2022	Phase 4
NCT02962492	University at Buffalo\|AstraZeneca	Evaluate Ketogenic Stress	November 2016	Phase 4
NCT05440591	Tan Tock Seng Hospital	Diabetes	April 1, 2019	Phase 4
NCT03710460	University of Guadalajara	Obesity	July 30, 2019	Phase 4
NCT05797935	Postgraduate Institute of Medical Education and Research	Pancreatic Lipomatosis	August 1, 2021	Phase 4
NCT00831779	AstraZeneca\|Astra Zeneca, Bristol-Myers Squibb	Type 2 Diabetes Mellitus	April 2009	Phase 2
NCT05759000	Chinese University of Hong Kong	Heart Failure	April 9, 2023
NCT03556033	Radboud University Medical Center	Diabetes Mellitus, Type 1\|Hypoglycemia\|Hypoglycemia Unawareness	November 23, 2018	Phase 2
NCT05621551	China National Center for Cardiovascular Diseases	Diabetes Mellitus, Type 2\|Cardiac Surgery	November 11, 2022	Phase 4
NCT02811484	Weill Medical College of Cornell University	Diabetes Mellitus, Type 2	June 2016	Phase 4
NCT02887677	Hellenic Society for Medical Education	Diabetes Mellitus	October 2016	Phase 4
NCT00162305	AstraZeneca\|Bristol-Myers Squibb	Diabetes Mellitus, Type 2	April 2005	Phase 2
NCT05042505	Medanta, The Medicity, India	Diabetes Mellitus\|Liver Transplant; Complications	January 1, 2022	Not Applicable
NCT04445714	AstraZeneca	Type 2 Diabetes Mellitus	April 7, 2021	Phase 4
NCT02564926	AstraZeneca	Diabetes Mellitus, Type 2	January 5, 2016	Phase 4
NCT05310916	Nidae Alaa\|Ain Shams University	Diabetic Retinopathy	June 6, 2022	Phase 3
NCT04956809	University of Pennsylvania\|Amgen	HFrEF	October 22, 2021	Phase 2
NCT05268926	Hiddo Lambers Heerspink\|AstraZeneca\|University Medical Center Groningen	Albuminuria	February 3, 2022	Phase 2
NCT01042977	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus\|Cardiovascular Disease\|Inadequate Glycaemic Control	March 2010	Phase 3
NCT02956811	University of Dundee\|NHS Tayside\|AstraZeneca	Type 2 Diabetes\|Left Ventricular Hypertrophy	February 14, 2017	Phase 4
NCT04881006	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Healthy Subjects	December 10, 2020	Phase 1
NCT04856969	Autotelicbio	Healthy Adult Volunteers	March 30, 2021	Phase 1
NCT02547935	AstraZeneca	Type 2 Diabetes Mellitus, CKD and Albuminuria	September 21, 2015	Phase 2\|Phase 3
NCT05429593	Novo Nordisk A+S	Healthy Volunteers	June 22, 2022	Phase 1
NCT02475070	Lund University	Type 2 Diabetes	January 2016	Phase 4
NCT05998525	Hilda Elizabeth Macías Cervantes\|Instituto Mexicano del Seguro Social	Diabete Type 2\|Unstable Angina\|Myocardial Infarction\|Diabetes Mellitus, Type 2	June 21, 2021	Phase 3
NCT04149067	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla\|AstraZeneca	Diabetes Mellitus, Type 2	June 5, 2017
NCT05424315	Omar Younis\|Ain Shams University\|National Heart Institute, Egypt	Anterior MI	October 1, 2021	Phase 2\|Phase 3
NCT03714594	University of Pisa	Type2 Diabetes Mellitus	July 24, 2018	Phase 2
NCT03959501	The University of Hong Kong	Type 2 Diabetes\|Ketonemia	August 16, 2017	Phase 4
NCT05966818	Ain Shams University	Nephrotic Syndrome	August 1, 2023	Phase 4
NCT02911792	The University of Texas Health Science Center at San Antonio\|AstraZeneca	Diabetes Mellitus, Type 2	December 20, 2016	Phase 4
NCT04707261	Xiangtan Central Hospital\|Second Xiangya Hospital of Central South University\|ZhuZhou Central Hospital	Anemia\|Heart Failure	August 6, 2021	Phase 4
NCT04706637	Kyung Hee University Hospital at Gangdong\|Dong-A ST Co., Ltd.	Bone Diseases, Metabolic\|Diabetes Mellitus, Type 2	February 1, 2021	Phase 4
NCT04717986	Instituto Mexicano del Seguro Social	Acute Myocardial Infarction\|Cardiovascular Morbidity\|Heart Failure\|Angina, Unstable	January 26, 2021	Not Applicable
NCT04730947	Mayo Clinic	Heart Failure With Preserved Ejection Fraction	February 24, 2021	Phase 2
NCT02371187	Christopher Bell\|AstraZeneca\|Colorado State University	Physical Activity	June 2015	Phase 2
NCT02397421	University of Dundee\|European Foundation for the Study of Diabetes	Heart Failure\|Diabetes	March 2015	Phase 4
NCT04634500	Daewoong Pharmaceutical Co. LTD.	T2DM (Type 2 Diabetes Mellitus)	November 18, 2020	Phase 3
NCT05848102	Sun Yat-sen University\|First Affiliated Hospital, Sun Yat-Sen University\|Third Affiliated Hospital, Sun Yat-Sen University\|Second Affiliated Hospital of Guangzhou Medical University\|Jieyang People´s Hospital\|Eighth Affiliated Hospital, Sun Yat-sen University\|Affiliated Hospital of Guangdong Medical University\|Yuebei People´s Hospital\|Zhongshan People´s Hospital, Guangdong, China	Functional Mitral Regurgitation	December 23, 2022	Phase 4
NCT05066516	Korea University Anam Hospital	Diabetes Mellitus	June 25, 2020	Phase 1
NCT04806633	G.Gennimatas General Hospital\|2nd Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens	Left Cardiac Catheterization\|Percutaneous Coronary Intervention\|Acute Kidney Injury\|Sodium-glucose Co-transporter 2 Inhibitors	April 1, 2021	Early Phase 1
NCT03007329	Medical University of Vienna\|AstraZeneca	Steatosis, Liver\|Type2 Diabetes	March 8, 2017	Phase 4
NCT05764057	Assistance Publique - Hôpitaux de Paris\|AstraZeneca	AMI\|STEMI\|NSTEMI\|Left Ventricular Dysfunction	March 2023	Phase 3
NCT02223065	AstraZeneca	Type 2 Diabetes Mellitus	September 2014	Phase 1
NCT01525238	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	July 1, 2012	Phase 1
NCT03152084	AstraZeneca	Diabetes Mellitus, Type 2\|Kidney Function Tests	July 12, 2017	Phase 4
NCT04899349	Novartis Pharmaceuticals\|Novartis	Breast Cancer	April 6, 2022	Phase 2
NCT02582814	AstraZeneca	Type 1 Diabetes Mellitus	October 26, 2015	Phase 3
NCT05014594	Postgraduate Institute of Medical Education and Research	Cirrhosis\|Ascites Hepatic	September 3, 2021	Phase 2
NCT04170543	AstraZeneca	Diabetic Kidney Disease	November 18, 2019	Phase 2
NCT00357370	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	October 2006	Phase 2\|Phase 3
NCT04739215	Hospital General Universitario Gregorio Marañon\|University of Navarra\|Instituto de Salud Carlos III\|Fundación para la Investigación Biomédica del Hospital Gregorio Maranon	Diabetes Mellitus, Type 2\|Heart Failure With Preserved Ejection Fraction	January 15, 2021	Phase 4
NCT02585804	University Health Network, Toronto\|AstraZeneca\|University of Toronto\|Toronto General Hospital	Focal Segmental Glomerulosclerosis	September 2015	Phase 4
NCT05345327	The George Institute\|The University of New South Wales\|Monash University\|University of Sydney	Type 2 Diabetes	June 1, 2022	Phase 3
NCT01257412	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	January 2012	Phase 3
NCT05601336	Beni-Suef University	PCO	January 15, 2022	Phase 3
NCT03877224	AstraZeneca	Heart Failure With Preserved Ejection Fraction (HFpEF)	April 4, 2019	Phase 3
NCT05196347	Kaohsiung Medical University	Chronic Kidney Diseases	March 1, 2022	Phase 3
NCT04707352	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia\|Spanish Society of Cardiology	Heart Failure	February 8, 2021	Phase 3
NCT01135446	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	May 2010	Phase 1
NCT05516498	AstraZeneca	Liver Cirrhosis	October 31, 2022	Phase 2
NCT02973477	University of Michigan\|AstraZeneca	Type2 Diabetes\|Cardiovascular Diseases	January 12, 2017	Phase 4
NCT04213677	Nanfang Hospital, Southern Medical University	Polycystic Ovary Syndrome	March 20, 2020	Phase 3
NCT04885712	Boryung Pharmaceutical Co., Ltd	Type2 Diabetes	May 28, 2021	Phase 3
NCT00859898	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	April 2009	Phase 3
NCT04735042	University of Pisa	Type 2 Diabetes\|Urinary Tract Infections	October 7, 2020
NCT02765204	Uppsala University\|AstraZeneca	Diabetes Mellitus, Type 2	March 2016	Phase 4
NCT05558098	Hospital Israelita Albert Einstein	Critical Illness\|Sepsis	November 1, 2022	Phase 3
NCT03199053	AstraZeneca	Diabetes Mellitus, Type 2	October 11, 2017	Phase 3
NCT05109949	Centro Universitario de Ciencias de la Salud, Mexico	Diabetes Mellitus Type 2 Without Complication	March 30, 2020	Phase 3
NCT03961659	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Type 2 Diabetes Mellitus\|Obesity\|Cognitive Impairment	May 2019	Not Applicable
NCT00904176	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	June 2009	Phase 1
NCT04195243	Centro Universitario de Ciencias de la Salud, Mexico	Type 2 Diabetes Mellitus	December 2, 2019	Phase 3
NCT01002807	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus (T2DM)	November 2009	Phase 1
NCT02969798	The University of Texas Health Science Center at San Antonio\|American Diabetes Association\|AstraZeneca\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Diabetes Mellitus, Type 2\|Impaired Glucose Tolerance (IGT)\|Impaired Fasting Glucose (IFG)	January 1, 2014	Not Applicable
NCT02413398	AstraZeneca	Type 2 Diabetes Mellitus	June 15, 2015	Phase 3
NCT02653482	Saint Luke´s Health System	Chronic Heart Failure With Reduced Systolic Function	March 3, 2016	Phase 4
NCT00855166	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	February 2009	Phase 3
NCT05236998	SK Chemicals Co., Ltd.	Healthy Subjects	November 3, 2021	Phase 1
NCT02635386	Woman´s\|AstraZeneca	Polycystic Ovary Syndrome\|Obesity	March 22, 2016	Phase 3
NCT02211742	Medical University Innsbruck\|Medical University of Graz\|University of Bern	Fasting Glucose\|Glucose Excursion\|Glycemic Control	August 2014	Phase 4
NCT04696185	Spanish Society of Cardiology\|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III	Aortic Stenosis\|Transcatether Aortic Valve Implantation	January 27, 2021	Phase 4
NCT02919345	University of Campinas, Brazil\|AstraZeneca	Diabetes Mellitus, Type 2\|Coronary Artery Disease\|Carotid Artery Diseases	January 2017	Phase 4
NCT05944016	Prof. Dr. O. Gross\|German Research Foundation\|University Hospital Goettingen	Chronic Kidney Failure in Children and Young Adults	December 2023	Phase 3
NCT02608905	Baylor College of Medicine	Type 2 Diabetes Mellitus	November 2015	Phase 4
NCT03982381	Uppsala University\|Uppsala University Hospital\|Swedish Healthcare Regions\|Swedish National Board of Health and Welfare\|The Swedish National Diabetes Register	Type 2 Diabetes	September 5, 2019	Phase 4
NCT05033054	University of Texas Southwestern Medical Center	Kidney Disease, Chronic\|Diabetes	November 20, 2022	Phase 1
NCT05998837	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy\|AstraZeneca	Chronic Kidney Disease\|Diabetes Mellitus, Type 2\|Hypertension	April 13, 2021	Phase 2\|Phase 3
NCT04014192	Peking Union Medical College Hospital	Type 2 Diabetes Mellitus	September 1, 2019	Phase 4
NCT04356742	Dong-A ST Co., Ltd.	Type 2 Diabetes	May 26, 2020	Phase 3
NCT02113241	University of Guadalajara	Metabolic Syndrome X	April 2014	Phase 2\|Phase 3
NCT02582840	AstraZeneca	Type 1 Diabetes Mellitus	October 2015	Phase 1
NCT03660683	Sabyasachi Sen\|George Washington University	Diabetes Mellitus, Type 2\|Cardiovascular Diseases	October 22, 2018	Phase 4
NCT04242758	University of Pisa	Renal Function Disorder\|Glucose Metabolism Disorders	June 4, 2019	Phase 4
NCT05468203	The George Institute\|University Medical Center Groningen\|Australian and New Zealand Intensive Care Society Clinical Trials Group	Acute Kidney Injury	September 1, 2023	Phase 3
NCT03704818	University of California, San Diego\|Juvenile Diabetes Research Foundation	Type1 Diabetes Mellitus	October 8, 2018	Phase 1
NCT01165268	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	August 2010	Phase 1
NCT04542291	Washington University School of Medicine\|National Institutes of Health (NIH)\|National Cancer Institute (NCI)	Pancreas Cancer\|Pancreatic Cancer\|Cancer of the Pancreas	February 25, 2021	Phase 1
NCT04298229	Vanderbilt University Medical Center\|AstraZeneca	Heart Failure\|Diabetes Mellitus, Type 2	April 1, 2020	Phase 3
NCT04724837	AstraZeneca	Chronic Kidney Disease	April 28, 2021	Phase 2
NCT02532855	Merck Sharp & Dohme LLC	Type 2 Diabetes Mellitus	October 20, 2015	Phase 3
NCT04575675	Cheng-Hsin General Hospital	Hypotension\|Heart Failure	May 29, 2020	Phase 4
NCT02981069	The University of Texas Health Science Center at San Antonio\|AstraZeneca	Diabetes Mellitus, Type 2	December 15, 2017	Phase 4
NCT05618223	Universitas Sebelas Maret	Rheumatic Heart Disease\|Heart Failure\|Mitral Stenosis	December 1, 2022	Phase 3
NCT05938712	University Health Network, Toronto	Kidney Transplant Recipients	September 1, 2023	Phase 2
NCT02722239	AstraZeneca\|Biocard	Diabetes Mellitus, Type 2	March 30, 2016	Phase 1
NCT04258371	University Health Network, Toronto\|Sunnybrook Health Sciences Centre\|MOUNT SINAI HOSPITAL	Cardiovascular Risk Factor	February 10, 2020	Phase 2
NCT05194592	Wonju Severance Christian Hospital	Type2 Diabetes\|Remodeling, Ventricular	January 7, 2022	Phase 4
NCT05957887	Mohamed Nabil Elkholy\|Helwan University	STEMI	April 15, 2022	Phase 3
NCT04287387	Peking Union Medical College Hospital\|Chinese Academy of Sciences	Type2 Diabetes Mellitus	March 2, 2020	Phase 4
NCT02268214	AstraZeneca\|Bristol-Myers Squibb	Type 1 Diabetes Mellitus	November 11, 2014	Phase 3
NCT05459701	Rehab Werida\|University of Alexandria\|Damanhour University	Nonalcoholic Fatty Liver Disease\|Type 2 Diabetes	May 1, 2022	Phase 4
NCT04304261	Third Military Medical University	Diabetes Mellitus, Type 2\|Cognitive Functions Confusion	April 1, 2020	Phase 3
NCT03592667	University of Guadalajara	Hypertension	February 14, 2019	Phase 4
NCT03377335	University of Palermo\|AstraZeneca\|University of Catania	Type 2 Diabetes Mellitus	December 22, 2017	Phase 4
NCT05420285	Assistance Publique - Hôpitaux de Paris	Heart Failure\|Reduced Ejection Fraction	June 26, 2022	Phase 2
NCT03313752	Andrea Giaccari\|Catholic University of the Sacred Heart	Type2 Diabetes Mellitus\|Stable Coronary Artery Disease	December 1, 2017	Phase 3
NCT04991571	AstraZeneca	Chronic Kidney Disease	July 29, 2021	Phase 1
NCT04363697	The TIMI Study Group\|AstraZeneca\|Worldwide Clinical Trials	Acute Heart Failure\|Heart Failure	September 24, 2020	Phase 4
NCT03970044	Consano Clinical Research, LLC	Diabetes Mellitus, Type 2	July 2, 2019	Phase 4
NCT03249506	Janssen Research & Development, LLC	Diabetes Mellitus, Type 2	May 12, 2016
NCT05762952	University of Virginia	Myocardial Ischemia	May 24, 2023	Phase 1
NCT05852704	Region Örebro County\|Odense University Hospital\|Aarhus University Hospital\|Örebro University, Sweden\|Sahlgrenska University Hospital, Sweden\|Göteborg University\|University of Leeds\|Brigham and Women´s Hospital\|Skane University Hospital\|London School of Hygiene and Tropical Medicine\|Harvard Medical School (HMS and HSDM)\|Swedish Heart Lung Foundation\|The Swedish Research Council	Chronic Coronary Syndrome\|Atrial Fibrillation	October 2, 2023	Phase 4
NCT05179356	Mads Ersbøll\|Rigshospitalet, Denmark	Pulmonary Arterial Hypertension\|Chronic Thromboembolic Pulmonary Hypertension	January 1, 2023	Phase 2
NCT00984867	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	October 2009	Phase 3
NCT05816733	Kun Hua\|Beijing Anzhen Hospital	Atrial Fibrillation Recurrence\|Cox Maze IV\|Atrial Fibrillation\|Patients With or Without Heart Failure and Diabetes	April 7, 2023	Phase 4
NCT04451837	Region Skane\|Göteborg University	Type2 Diabetes	September 10, 2020	Phase 2
NCT00839683	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	February 2009	Phase 1
NCT05162690	Postgraduate Institute of Medical Education and Research	Diabetic Peripheral Neuropathy	May 1, 2022	Phase 2\|Phase 3
NCT00908271	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	July 2009	Phase 1
NCT02700334	University of Guadalajara	Prediabetes\|Impaired Fasting Glucose\|Impaired Glucose Tolerance	October 2016	Phase 4
NCT05685394	University of Campinas, Brazil	End-stage Kidney Disease	January 24, 2023	Phase 4
NCT01535677	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	April 2013	Phase 1
NCT04249778	Emory University	Heart Failure\|Diabetes	July 29, 2020	Phase 4
NCT01068756	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	March 2010	Phase 1
NCT04923295	An-Najah National University	Peritoneal Dialysis Complication\|Ultrafiltration Failure	June 2, 2021	Not Applicable
NCT04796428	Center for Outcomes Research and Clinical Epidemiology, Italy\|Italian Society of Diabetology	Diabetes Mellitus, Type 2	June 30, 2021	Phase 4
NCT05308160	National Taiwan University Hospital	Fatty Liver	June 28, 2021	Phase 3
NCT02987738	Kinderkrankenhaus auf der Bult\|AstraZeneca\|Alcedis GmbH	Type1diabetes	February 9, 2017	Phase 1
NCT05105698	LG Chem	Healthy Volunteers	January 1, 2022	Phase 1
NCT04595370	AstraZeneca	Heart Failure\|Chronic Kidney Disease	January 26, 2021	Phase 2
NCT04234867	Kinderkrankenhaus auf der Bult	Type 1 Diabetes\|Diabetic Ketoacidosis	May 18, 2022	Phase 1
NCT02060201	AstraZeneca	Type 2 Diabetes Mellitus	February 2014	Phase 1
NCT02520518	Christopher Bell\|AstraZeneca\|Colorado State University	Weight Loss	August 2015	Phase 2
NCT04818034	University of California, San Francisco	Cystinuria	May 2, 2025	Phase 2
NCT04640493	Columbia University	Heart Failure\|Sleep Disordered Breathing	December 2023	Phase 2
NCT04882813	Brigham and Women´s Hospital	Chronic Kidney Disease	December 13, 2020
NCT02501616	Seoul National University Hospital	Endothelial Function\|Type 2 Diabetes	December 2014	Phase 4
NCT02592421	The University of Texas Health Science Center at San Antonio\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Type II Diabetes Mellitus	October 23, 2015	Phase 3
NCT00680745	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	April 2008	Phase 3
NCT03361098	Amsterdam UMC, location VUmc\|AstraZeneca	Type 2 Diabetes Mellitus\|Obesity	September 18, 2017	Phase 4
NCT01606007	AstraZeneca	Type 2 Diabetes	July 2012	Phase 3
NCT03338855	AstraZeneca	Diabetes Mellitus, Type 2\|Skeletal Muscle Insulin Sensitivity	March 5, 2018	Phase 4
NCT05717257	Monaldi Hospital	Dapagliflozin Adverse Reaction\|Efficacy\|Systemic Right Ventricle	August 1, 2022	Phase 4
NCT03138356	AstraZeneca	Type 2 Diabetes Mellitus	May 25, 2017	Phase 1
NCT01294436	AstraZeneca\|Bristol-Myers Squibb	Type2 Diabetes\|High Blood Sugar	February 2011	Phase 3
NCT02229396	AstraZeneca	Diabetes Mellitus	September 4, 2014	Phase 3
NCT00972244	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	August 2009	Phase 2
NCT02925559	Centro de Diabetes Curitiba Ltda\|AstraZeneca	Diabetes Mellitus, Type 2	October 2016	Phase 4
NCT05374291	University Medical Center Groningen\|AstraZeneca\|Dutch Kidney Foundation	Kidney Disease, Chronic\|Renal Transplant Failure\|Heart Failure\|Kidney Failure\|Death	November 8, 2022	Phase 3
NCT05505994	Daewoong Pharmaceutical Co. LTD.	Diabetes Mellitus\|Diabetes Mellitus, Type 2\|Glucose Metabolism Disorders\|Metabolic Disease\|Endocrine System Diseases	September 2022	Phase 3
NCT05179668	Medical University of Vienna\|Vienna Dialysis Center	Kidney Failure\|Hemodialysis\|Diabetes Mellitus, Type 2\|Chronic Kidney Disease\|Left Ventricular Hypertrophy	October 1, 2022	Phase 2
NCT04080518	National Heart Centre Singapore\|Duke-NUS Medical School (Singapore)	Diabetes Mellitus\|Heart Failure	November 11, 2019	Phase 4
NCT03006471	University of Guadalajara	PreDiabetes\|Prehypertension	March 30, 2016	Phase 4
NCT03331289	The University of Texas Health Science Center at San Antonio\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Diabetes Mellitus, Type 2	February 28, 2018	Phase 4
NCT04330079	CHEOL WHAN LEE, M.D., Ph.D\|Asan Medical Center	Coronary Artery Disease\|Prediabetic State	May 21, 2020	Phase 4
NCT05050500	Qingdao Central Hospital	Myocardial Infarction\|Diabete Type 2\|Glucose Intolerance	December 8, 2023	Phase 4
NCT05565976	Jaime Daniel Mondragon\|Hospital General León\|Hospital General de Zona IMSS N0. 21\|University Medical Center Groningen\|Universidad de Guanajuato	Stroke, Ischemic\|Mild Cognitive Impairment\|Dementia, Vascular\|Metabolic Syndrome	August 1, 2020	Phase 2\|Phase 3
NCT05550441	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Heart Failure	November 15, 2022	Phase 4
NCT05915949	Seoul National University Bundang Hospital	Diabetes Type 2	January 1, 2022	Phase 4
NCT02253121	Slotervaart Hospital\|AstraZeneca\|Isala\|Spaarne Gasthuis	Hyperglycemia Steroid-induced	February 2015	Phase 4
NCT03030235	Saint Luke´s Health System	Chronic Heart Failure With Preserved Systolic Function	March 1, 2017	Phase 4
NCT03762850	Travere Therapeutics, Inc.	Immunoglobulin A Nephropathy	December 11, 2018	Phase 3
NCT05139914	Boston University\|American Heart Association	Diabetes Mellitus, Type 2\|Endothelial Dysfunction	May 31, 2022	Phase 4
NCT02325206	Kinderkrankenhaus auf der Bult	Type 1 Diabetes	December 2014	Phase 1
NCT03537131	University of Oxford\|The Leona M. and Harry B. Helmsley Charitable Trust\|Oxford Brookes University	Diabetes Mellitus, Type 1	June 2, 2018	Phase 2
NCT03364985	Daewoong Pharmaceutical Co. LTD.	Healthy	December 3, 2017	Phase 1
NCT04782245	Hospices Civils de Lyon	End-stage Heart Failure	September 2022	Phase 2
NCT04255238	LG Chem	Diabetes Mellitus, Type 2	June 30, 2020	Phase 3
NCT05521984	Washington University School of Medicine\|Children´s Discovery Institute	Pediatric Brain Tumor	April 3, 2023	Phase 1
NCT05849220	Institute of Liver and Biliary Sciences, India	NAFLD Cirrhosis	May 15, 2023	Not Applicable

分子量

408.87

Formula

C₂₁H₂₅ClO₆

CAS 号

461432-26-8

性状

固体

颜色

White to off-white

中文名称

达格列净；达帕格列净；达格列嗪

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 100 mg/mL (244.58 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : 50 mg/mL (122.29 mM; 超声助溶)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4458 mL	12.2288 mL	24.4577 mL
5 mM	0.4892 mL	2.4458 mL	4.8915 mL
10 mM	0.2446 mL	1.2229 mL	2.4458 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (6.11 mM); 澄清溶液
方案二

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.11 mM); 澄清溶液
方案三

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.09 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案四

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.09 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案五

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.09 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案六

请依序添加每种溶剂： 1% DMSO 99% Saline
Solubility: ≥ 0.5 mg/mL (1.22 mM); 澄清溶液

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： PBS
Solubility: 33.33 mg/mL (81.52 mM); 澄清溶液; 超声助溶 (<60°C)

扫码获得
动物溶解方案

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

纯度 & 产品资料

纯度： 99.97%

选择批次：

Data Sheet (638 KB) SDS (393 KB)

COA (285 KB)HNMR (278 KB)RP-HPLC (242 KB)LCMS (88 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Pelissier T, et al. The orofacial capsaicin test in rats: effects of different capsaicin concentrations and morphine. Pain. 2002 Mar;96(1-2):81-7. [Content Brief]

Dapagliflozin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	2.4458 mL	12.2288 mL	24.4577 mL	61.1441 mL
	5 mM	0.4892 mL	2.4458 mL	4.8915 mL	12.2288 mL
	10 mM	0.2446 mL	1.2229 mL	2.4458 mL	6.1144 mL
	15 mM	0.1631 mL	0.8153 mL	1.6305 mL	4.0763 mL
	20 mM	0.1223 mL	0.6114 mL	1.2229 mL	3.0572 mL
	25 mM	0.0978 mL	0.4892 mL	0.9783 mL	2.4458 mL
	30 mM	0.0815 mL	0.4076 mL	0.8153 mL	2.0381 mL
	40 mM	0.0611 mL	0.3057 mL	0.6114 mL	1.5286 mL
	50 mM	0.0489 mL	0.2446 mL	0.4892 mL	1.2229 mL
	60 mM	0.0408 mL	0.2038 mL	0.4076 mL	1.0191 mL
	80 mM	0.0306 mL	0.1529 mL	0.3057 mL	0.7643 mL
	100 mM	0.0245 mL	0.1223 mL	0.2446 mL	0.6114 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Keywords:

Dapagliflozin461432-26-8BMS-512148达格列净达帕格列净达格列嗪BMS512148BMS 512148SGLTSodium-dependent glucose cotransportersInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Dapagliflozin (Synonyms: 达格列净; BMS-512148)

Customer Review

Other Forms of Dapagliflozin:

MCE 顾客使用本产品发表的 43 篇科研文献

Dapagliflozin 相关产品

•相关化合物库:

查看 SGLT 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Dapagliflozin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Dapagliflozin (Synonyms: 达格列净; BMS-512148)

Customer Review

Other Forms of Dapagliflozin:

MCE 顾客使用本产品发表的 43 篇科研文献

Dapagliflozin 相关产品

•相关化合物库:

查看 SGLT 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Dapagliflozin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z